Lloyd Shabazz
Hematology & Oncology · Portsmouth, VANPI 1720082183
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,018 of the $15,704 with a category attached, or 82.9%. Bristol Myers Squibb accounts for 63.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $14,167 and has fallen 95.8% since, to $600 in 2021. Among hematology & oncology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 62 payments — averaging $253.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$10K
- Rigel Pharmaceuticals, Inc.$4K
- Pfizer$940
- Johnson & Johnson$250
- Sanofi$155
- Takeda Pharmaceuticals U.S.A., Inc.$135
- plus $321 from 11 others
Across 14 payments — averaging $14,682 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$160K
- Incyte Corporation$31K
- Pfizer$15K
- Spectrum Pharmaceuticals Inc.$355
What the payments were for
- Consulting fees$6744%
- Speaking & faculty fees$13,01883%
- Travel & lodging$6734%
- Food & beverage$1,3228%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 15 | $10,006 |
| Rigel Pharmaceuticals, Inc. | 8 | $3,896 |
| Pfizer | 1 | $940 |
| Johnson & Johnson(2 entities) | 14 | $250 |
| Sanofi | 3 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $135 |
| Ipsen Biopharmaceuticals, Inc | 3 | $47 |
| Daiichi Sankyo Inc. | 3 | $42 |
| Astellas Pharma US Inc | 2 | $41 |
| Amgen | 2 | $38 |
| Novartis | 2 | $37 |
| Puma Biotechnology, Inc. | 2 | $33 |
| AstraZeneca | 1 | $21 |
| Grifols USA, LLC | 1 | $20 |
| Karyopharm Therapeutics Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $15 |
| Bioverativ Therapeutics Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,704 in reported general payments places this provider in the 90th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Portsmouth
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
- Sekwon JangFairfax$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.